Haleon
Description
About Haleon
On July 18, 2022, Haleon completed its spin off from GlaxoSmithKline (GSK), officially becoming an independent and dedicated company focused on consumer health, and listed on the London Stock Exchange (LSE) and the New York Stock Exchange (NYSE), respectively. The Haleon Suzhou factory is one of the important supply bases for Haleon in the Asia Pacific region.
Established in 1991, it mainly produces various prescription and over-the-counter drugs such as calcium supplements (calcium carbonate D3 tablet series), multiple vitamins (Shancun tablets), and anti cold and cough medicine (Huifening).
Project Background
Project situation
Haleon Suzhou factory started cooperation with Climate Bridge in September 2022. Under strict adherence to PAS2060 carbon neutrality certification standards, Climate Bridge has helped the Haleon Suzhou factory achieve carbon neutrality within its operating range (Scope 1 and Scope 2) from January 1, 2021 to December 31, 2021, helping it become the first carbon neutrality factory in the consumer health sector in China.
Monday to Friday 8:30-18:30
Block B, 24th Floor, Jiangong Building, No. 33 Fushan Road, Pudong New Area, Shanghai
Follow us：
Follow WeChat
X
The Climate Bridge Technical Advisor will wholeheartedly serve you!
